Linagliptin Parent Nucleus Intermediate CAS 853029-57-9 Purity ≥99.0% Factory

Name: Linagliptin Parent Nucleus Intermediate  CAS: 853029-57-9 Purity: ≥99.0% Appearance: White to Light Yellow Powder Intermediate for Linagliptin (CAS: 668270-12-0) for the treatment type II diabetes mellitus High Quality, Commercial Production E-Mail: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.Manufacturer Supply Linagliptin and Related Intermediates: Linagliptin CAS 668270-12-0 Linagliptin Parent Nucleus Intermediate CAS 853029-57-9 8-Bromo-3-Methylxanthine CAS 93703-24-3 8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine CAS 666816-98-4 2-(Chloromethyl)-4-Methylquinazoline CAS 109113-72-6 (R)-3-(Boc-Amino)piperidine CAS 309956-78-3 (R)-(-)-3-Aminopiperidine Dihydrochloride CAS 334618-23-4 1-Bromo-2-Butyne CAS 3355-28-0
Item Specifications
Appearance White to Light Yellow Powder
Identification  IR/HPLC
Purity ≥99.0%
Water (K.F) ≤1.0%
Residue on Ignition ≤0.50%
Total Impurities ≤1.0%
Test Standard Enterprise Standard
Usage Intermediate for Linagliptin (CAS: 668270-12-0)

Description:

Specifications:

Package & Storage:

Chemical Name 8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
Synonyms Linagliptin Parent Nucleus; Linagliptin Intermediate F
CAS Number 853029-57-9
CAT Number RF-PI502
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C20H17BrN6O2
Molecular Weight 453.29
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (CAS: 853029-57-9) is the parent nucleus of Linagliptin (CAS: 668270-12-0). Linagliptin (trade names Tradjenta and Trajetna) is an inhibitor of dipeptidyl peptidase-4 (DPP-4) that was approved by the U.S. FDA in May 2011 for the treatment of Type 2 diabetes along with diet and exercise.  Linagliptin (BI-1356) has been described as a potent highly selective, slow-off rate and long acting inhibitor of DPP-4.  Linagliptin arose from optimization efforts of xanthine-based DPP-4 inhibitors with the initial lead identified from an HTS campaign.

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours